CB-011, an anti-BCMA allogeneic CAR-T engineered with CRISPR/CAS12a to KO not only TRAC but also β2M and co-express a β2M-HLA-E fusion peptide, is currently being evaluated in the CaMMouflage Phase 1 study, and has demonstrated promising preclinical data leading to significant improvement in anti-tumor activity durability [174]. This evidence concerns the gene B2M and neoplasm.